207 related articles for article (PubMed ID: 35198082)
21. Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation.
Peterse EFP; Niessen B; Addie RD; de Jong Y; Cleven AHG; Kruisselbrink AB; van den Akker BEWM; Molenaar RJ; Cleton-Jansen AM; Bovée JVMG
Br J Cancer; 2018 Apr; 118(8):1074-1083. PubMed ID: 29576625
[TBL] [Abstract][Full Text] [Related]
22. Increased levels of hypoxia-inducible factor-1α are associated with Bcl-xL expression, tumor apoptosis, and clinical outcome in chondrosarcoma.
Chen C; Zhou H; Wei F; Jiang L; Liu X; Liu Z; Ma Q
J Orthop Res; 2011 Jan; 29(1):143-51. PubMed ID: 20661931
[TBL] [Abstract][Full Text] [Related]
23. PRP‑1 significantly decreases the ALDHhigh cancer stem cell population and regulates the aberrant Wnt/β‑catenin pathway in human chondrosarcoma JJ012 cells.
Hoyt AK; Moran A; Granger C; Sedani A; Saigh S; Brown J; Galoian KA
Oncol Rep; 2019 Jul; 42(1):103-114. PubMed ID: 31180539
[TBL] [Abstract][Full Text] [Related]
24. Correlation of hypoxic signalling to histological grade and outcome in cartilage tumours.
Boeuf S; Bovée JV; Lehner B; Hogendoorn PC; Richter W
Histopathology; 2010 Apr; 56(5):641-51. PubMed ID: 20459575
[TBL] [Abstract][Full Text] [Related]
25. Hypoxia-inducible factor 1-alpha and vascular endothelial growth factor in cartilage tumors.
Kouvaras E; Christoni Z; Siasios I; Malizos K; Koukoulis GK; Ioannou M
Biotech Histochem; 2019 May; 94(4):283-289. PubMed ID: 30605014
[TBL] [Abstract][Full Text] [Related]
26. Brain-derived neurotrophic factor promotes VEGF-C-dependent lymphangiogenesis by suppressing miR-624-3p in human chondrosarcoma cells.
Lin CY; Wang SW; Chen YL; Chou WY; Lin TY; Chen WC; Yang CY; Liu SC; Hsieh CC; Fong YC; Wang PC; Tang CH
Cell Death Dis; 2017 Aug; 8(8):e2964. PubMed ID: 28771226
[TBL] [Abstract][Full Text] [Related]
27. A genetic model for central chondrosarcoma evolution correlates with patient outcome.
Cross W; Lyskjær I; Lesluyes T; Hargreaves S; Strobl AC; Davies C; Waise S; Hames-Fathi S; Oukrif D; Ye H; Amary F; Tirabosco R; Gerrand C; Baker T; Barnes D; Steele C; Alexandrov L; Bond G; ; Cool P; Pillay N; Van Loo P; Flanagan AM
Genome Med; 2022 Aug; 14(1):99. PubMed ID: 36042521
[TBL] [Abstract][Full Text] [Related]
28. Hypoxia induces HIF-1alpha and VEGF expression in chondrosarcoma cells and chondrocytes.
Lin C; McGough R; Aswad B; Block JA; Terek R
J Orthop Res; 2004 Nov; 22(6):1175-81. PubMed ID: 15475194
[TBL] [Abstract][Full Text] [Related]
29. Genome-wide transcriptional analyses of Chinese patients reveal cell migration is attenuated in IDH1-mutant glioblastomas.
Hu H; Wang Z; Liu Y; Zhang C; Li M; Zhang W; Wang K; Cai J; Cheng W; Huang H; Jiang T
Cancer Lett; 2015 Feb; 357(2):566-74. PubMed ID: 25511738
[TBL] [Abstract][Full Text] [Related]
30. Distinct Roles of Glutamine Metabolism in Benign and Malignant Cartilage Tumors With IDH Mutations.
Zhang H; Puviindran V; Nadesan P; Ding X; Shen L; Tang YJ; Tsushima H; Yahara Y; Ban GI; Zhang GF; Karner CM; Alman BA
J Bone Miner Res; 2022 May; 37(5):983-996. PubMed ID: 35220602
[TBL] [Abstract][Full Text] [Related]
31. Oncogenic MicroRNA-20a is downregulated by the HIF-1α/c-MYC pathway in IDH1 R132H-mutant glioma.
Xu Q; Ahmed AK; Zhu Y; Wang K; Lv S; Li Y; Jiang Y
Biochem Biophys Res Commun; 2018 May; 499(4):882-888. PubMed ID: 29625108
[TBL] [Abstract][Full Text] [Related]
32. Does PARP Inhibition Sensitize Chondrosarcoma Cell Lines to Chemotherapy or Radiotherapy? Results From a Three-dimensional Spheroid Cell Model.
Palubeckaitė I; Venneker S; van den Akker BEWM; Briaire-de Bruijn IH; Boveé JVMG
Clin Orthop Relat Res; 2023 Mar; 481(3):608-619. PubMed ID: 36729612
[TBL] [Abstract][Full Text] [Related]
33. Visfatin Facilitates VEGF-D-Induced Lymphangiogenesis through Activating HIF-1α and Suppressing miR-2277-3p in Human Chondrosarcoma.
Song CY; Hsieh SL; Yang SY; Lin CY; Wang SW; Tsai CH; Lo YS; Fong YC; Tang CH
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791180
[TBL] [Abstract][Full Text] [Related]
34. Periosteal chondrosarcoma: a histopathological and molecular analysis of a rare chondrosarcoma subtype.
Cleven AH; Zwartkruis E; Hogendoorn PC; Kroon HM; Briaire-de Bruijn I; Bovée JV
Histopathology; 2015 Oct; 67(4):483-90. PubMed ID: 25648524
[TBL] [Abstract][Full Text] [Related]
35. IDH1 mutations are not found in cartilaginous tumours other than central and periosteal chondrosarcomas and enchondromas.
Damato S; Alorjani M; Bonar F; McCarthy SW; Cannon SR; O'Donnell P; Tirabosco R; Amary MF; Flanagan AM
Histopathology; 2012 Jan; 60(2):363-5. PubMed ID: 22074484
[No Abstract] [Full Text] [Related]
36. Atypical cartilage in type II germ cell tumors of the mediastinum show significantly different patterns of IDH1/2 mutations from conventional chondrosarcoma.
Warmke LM; Cheng L; Sperling RM; Sen JD; Ulbright TM
Mod Pathol; 2022 Nov; 35(11):1636-1643. PubMed ID: 35660795
[TBL] [Abstract][Full Text] [Related]
37. Frequent IDH1/2 mutations in intracranial chondrosarcoma: a possible diagnostic clue for its differentiation from chordoma.
Arai M; Nobusawa S; Ikota H; Takemura S; Nakazato Y
Brain Tumor Pathol; 2012 Oct; 29(4):201-6. PubMed ID: 22323113
[TBL] [Abstract][Full Text] [Related]
38. The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.
Tinoco G; Wilky BA; Paz-Mejia A; Rosenberg A; Trent JC
Am Soc Clin Oncol Educ Book; 2015; ():e648-55. PubMed ID: 25993236
[TBL] [Abstract][Full Text] [Related]
39. Adiponectin promotes VEGF-A-dependent angiogenesis in human chondrosarcoma through PI3K, Akt, mTOR, and HIF-α pathway.
Lee HP; Lin CY; Shih JS; Fong YC; Wang SW; Li TM; Tang CH
Oncotarget; 2015 Nov; 6(34):36746-61. PubMed ID: 26468982
[TBL] [Abstract][Full Text] [Related]
40. A system-level approach identifies HIF-2α as a critical regulator of chondrosarcoma progression.
Kim H; Cho Y; Kim HS; Kang D; Cheon D; Kim YJ; Chang MJ; Lee KM; Chang CB; Kang SB; Kang HG; Kim JH
Nat Commun; 2020 Oct; 11(1):5023. PubMed ID: 33024108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
